Comparative effectiveness of azathioprine in Crohn’s disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients

Abstract Background Studies have reported good efficacy outcomes for patients with inflammatory bowel disease (IBD) treated with biosimilars. There are limited long term data. We assessed the long-term efficacy data and safety after switching from adalimumab to adalimumab biosimilar Imraldi in patients with IBD. Methods A prospective single-centre observational study involving patients with Crohn’s disease or ulcerative colitis switched from adalimumab originator to adalimumab biosimilar and reviewed up to 24months. Efficacy and loss of response were measured using the Harvey–Bradshaw (HB) index and partial Mayo score for patients with Crohn’s disease and ulcerative colitis respectively. Blood tests including C-reactive protein, adalimumab drug levels and antidrug antibodies were monitored. We have recorded side effects and possible serious adverse effects including COVID 19 infection. Results 113 patients were switched to Adalimumab biosimilar Imraldi from Adalimumab originator between January 2019 to March 2019. After 12 months of treatment, 25 patients interrupted treatment and 89 (78.8%) continued. These were analysed after 24 months of treatment - 57 (52.3%) continued on Imraldi. Of those who discontinued, 9 were switched back to Adalimumab originator due to side effects, and 34 stopped treatment - 16 patients due to loss of response, 11 patients developed antibodies, 5 underwent a surgery, 4 were in remission and 4 did not tolerate side effects. There was no statistical difference in CRP or Adalimumab levels prior to switch, at 12 months and at 24 months between the patients who continued or discontinued treatment. Overall, 18 of the patients who completed 24 months of treatment reported side effects, most frequently pain after injection (9 patients), followed by skin rash and recurrent infections (in 3 patients each). No patient was diagnosed with COVID 19 during until now. Conclusion After 24 months of follow up, 52.3% patients continued on adalimumab biosimilar and no serious side effects were reported. In particular, none of our patients acquired COVID 19 infection.

Download Full-text

Long term follow up of through the endoscope balloon dilatation as compared to strictureplasty and bowel resection of intestinal strictures in crohn's disease

Zeitschrift für Gastroenterologie ◽

10.1055/s-0031-1285149 ◽

2011 ◽

Vol 49 (08) ◽

Author(s):

E Krauss ◽

H Kessler ◽

A Gottfried ◽

W Hohenberger ◽

M Neurath ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Balloon Dilatation ◽

Bowel Resection ◽

Long Term Follow Up

Download Full-text

W1260 Maintenance of Clinical Benefit in Crohn's Disease Patients After Discontinuation of Infliximab: Long Term Follow-up of a Single Center Cohort

Gastroenterology ◽

10.1016/s0016-5085(10)63151-4 ◽

2010 ◽

Vol 138 (5) ◽

pp. S-685

Author(s):

Alistair W. Waugh ◽

Karen Wong ◽

Richard N. Fedorak

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Clinical Benefit ◽

Single Center ◽

Long Term Follow Up

Download Full-text

Mo1806 Natural History of Perianal Crohn's Disease: Long-Term Follow-Up on a Population-Based Cohort

Gastroenterology ◽

10.1016/s0016-5085(16)32649-x ◽

2016 ◽

Vol 150 (4) ◽

pp. S781-S782

Author(s):

Rabilloud Marie-Laure ◽

Charlène Brochard ◽

Emma Bajeux ◽

Siproudhis Laurent ◽

Jean-François Viel ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Natural History ◽

Population Based ◽

Perianal Crohn’S Disease ◽

Long Term Follow Up ◽

History Of ◽

Perianal Crohn's Disease

Download Full-text

Improved Biochemical Parameters in Patients Who Undergo Early Resection in Isolated Ileocaecal Crohn’s Disease

Surgery Research and Practice ◽

10.1155/2017/4396573 ◽

2017 ◽

Vol 2017 ◽

pp. 1-5

Author(s):

Mirzafaraz Saeed ◽

Hari Hullur ◽

Amro Salem ◽

Abbas Ali ◽

Yousif Sahib ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Surgical Resection ◽

Complete Blood Count ◽

Long Term Results ◽

Number Of Patients ◽

Long Term Follow Up ◽

One Year

Introduction. The aim of this study is to evaluate the outcome of introduction of early surgery in the course of isolated ileocecal Crohn’s disease, where there is no absolute indication of surgery. Methods. Observational study involving patients with isolated ileocecal Crohn’s disease who underwent early surgical resection (within one year of the presentation of the hospital). A complete blood count, ESR, and CRP were done and compared between the preoperative value, 1st postoperative visit (3-4 weeks), and last follow-up visit. Statistical analysis was done using Analysis of Variance (ANOVA) to compare the different figures. Results. There was a statistically significant increase in the hemoglobin levels between preoperative, postoperative, and long-term follow-up and a significant decrease in leukocyte count between the pre- and postoperative values (F=19.8, p<0.001 and F=8.9, p=0.002, resp.). Similarly, the ESR and CRP values were decreased significantly at long-term follow-up (F=8.5, p=0.019 and F=8.3, p=0.013, resp.). Conclusion. Early surgical resection in isolated ileocaecal Crohn’s disease achieved significant biochemical improvements. These successful results in this small number of patients indicate that early surgical intervention may provide better outcomes. These initial results encourage larger and comparative studies of long-term results versus long-term use of biological agents.

Download Full-text